The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trial

BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio (RR)=0.79, 95%CI 0.69–0.91). The U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) trial showed no su...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: de Koning, Harry J, Gulati, Roman, Moss, Sue M, Hugosson, Jonas, Pinsky, Paul F, Berg, Christine D, Auvinen, Anssi, Andriole, Gerald L, Roobol, Monique J, Crawford, E. David, Nelen, Vera, Kwiatkowski, Maciej, Zappa, Marco, Luján, Marcos, Villers, Arnauld, de Carvalho, Tiago M, Feuer, Eric J, Tsodikov, Alex, Mariotto, Angela B, Heijnsdijk, Eveline AM, Etzioni, R
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839977/
https://ncbi.nlm.nih.gov/pubmed/29211316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31178
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares